血液透析研究中Kt/Vurea与非尿素小分子溶质水平
血液透析(HEMO)研究显示高剂量透析单池Kt/Vurea 1.71较标准治疗1.32无获益。本分析在1281例患者中评估高剂量治疗是否降低尿素以外小分子溶质水平,发现部分溶质降低有限且与全因死亡率无关,提示仅基于尿素的指数不足以衡量透析充分性。
要点
- 高剂量透析对硫酸对甲酚和非对称二甲基精氨酸水平无降低。
- 高剂量透析使氧化三甲胺降低9%、硫酸吲哚酚降低11%、甲基胍降低22%。
- 所有溶质水平与全因死亡率无显著相关。
核心结论
- 未能更大程度降低溶质水平可能解释HEMO研究中高Kt/Vurea治疗未能改善结局。
- 非尿素溶质水平在患者间差异很大,而实现的Kt/Vurea仅解释其中很小部分变异。
- 仅基于尿素的指数不足以衡量透析充分性。
研究设计与样本
- HEMO研究的事后分析,在1281例患者随机化后≥3个月进行测量。
主要发现
- 与标准治疗相比,高剂量治疗对硫酸对甲酚和非对称二甲基精氨酸水平无降低。
- 高剂量治疗使氧化三甲胺降低9%(95%CI -2%至-15%)、硫酸吲哚酚降低11%(95%CI -6%至-15%)、甲基胍降低22%(95%CI -18%至-27%)。
- 另外三种小分子溶质水平也略有降低,尿素水平降低9%。
- 所有测量的溶质水平与全因死亡率无显著相关。
- 模型提示治疗间歇性以及非透析清除和/或溶质生成增加可解释较高Kt/Vurea下溶质水平降低有限。
关键数值与推荐
- 高剂量透析单池Kt/Vurea为1.71,标准治疗单池Kt/Vurea为1.32。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Hemodialysis (HEMO) Study showed that high-dose hemodialysis providing a single-pool Kt/Vurea of 1.71 provided no benefit over a standard treatment providing a single-pool Kt/Vurea of 1.32. Here, we assessed whether the high-dose treatment used lowered plasma levels of small uremic solutes other than urea. Measurements made ≥3 months after randomization in 1281 patients in the HEMO Study showed a range in the effect of high-dose treatment compared with that of standard treatment: from no reduction in the level of p-cresol sulfate or asymmetric dimethylarginine to significant reductions in the levels of trimethylamine oxide (-9%; 95% confidence interval [95% CI], -2% to -15%), indoxyl sulfate (-11%; 95% CI, -6% to -15%), and methylguanidine (-22%; 95% CI, -18% to -27%). Levels of three other small solutes also decreased slightly; the level of urea decreased 9%. All-cause mortality did not significantly relate to the level of any of the solutes measured. Modeling indicated that the intermittency of treatment along with the presence of nondialytic clearance and/or increased solute production accounted for the limited reduction in solute levels with the higher Kt/Vurea In conclusion, failure to achieve greater reductions in solute levels may explain the failure of high Kt/Vurea treatment to improve outcomes in the HEMO Study. Furthermore, levels of the nonurea solutes varied widely among patients in the HEMO Study, and achieved Kt/Vurea accounted for very little of this variation. These results further suggest that an index only on the basis of urea does not provide a sufficient measure of dialysis adequacy.
引用
- Meyer TW, Sirich TL, Fong KD, et al. Kt/Vurea and Nonurea Small Solute Levels in the Hemodialysis Study. J Am Soc Nephrol. 2016. PMID: 27026365
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。